Option chain shows key data for Genprex's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Genprex.

Genprex (NASDAQ:GNPX) Stock, Option Chain

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Gamestop, Lululemon, Uber, Ulta Beauty And Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APVO

AREB

ASIX

BIAF

GITS

GNPX

ICCT

KGEI

Penguin Solutions, Inc. - Ordinary Shares

PENG

PMAX

PTIX

RXST

TIVC

TOPW

TYRA

Why Penguin Solutions Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Market Impact And Global Democracy

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket

Lattice Semiconductor

ACLS

AMKR

BHAT

BNAI

FLNC

HLIT

LIXT

LSCC

NLSP

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Genprex Inc

Press Releases

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex to Participate at BIO 2025 International Convention

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

180 Life Sciences

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

CEL-SCI

Ensysce Biosciences

Galecto

IN8bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

PharmaCyte Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Synaptogenix

Tharimmune

Turnstone Biologics

Xenetic Biosciences

HC Wainwright & Co.

Dawson James

Screenshot 2023-07-10 at 5.56.06 PM

Biotech

General

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Comments

Genprex

Genprex (GNPX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell